SOUTH PLAINFIELD, NJ, April 14, 2015 /PRNewswire/ -- Prolong announced today that it had presented data on its flagship product SANGUINATE, reporting its novel ability to rapidly reverse sickling of human red blood cells...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/prolongnews2.jpg?time=160181049636125IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2015-04-14 12:34:392015-05-27 20:03:12Prolong Pharmaceuticals Presents Data on Unique “Un-Sickling” In Vitro Activity Observed in Sickle Cell Investigational Drug SANGUINATE™
SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- Prolong announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its flagship product SANGUINATE...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/prolongnews2.jpg?time=160181049636125IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2015-04-08 13:38:512015-05-27 20:04:00Prolong Pharmaceuticals’ Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA
Prolong recently announced the expansion of its South Plainfield, New Jersey, biologics processing facility, adding 24,000 square feet in a move that essentially doubles its original manufacturing capacity to 48,000 square feet...
Prolong Pharmaceuticals LLC announced the expansion of its South Plainfield, N.J., manufacturing facility. A new long-term lease on the space adjoining its current facility is adding 24,000 square feet to the existing 24,000 square feet. In addition, the company secured 12,000 square feet of new executive and administrative space...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/pharmaceuticalmanulogo.png?time=160181049627130IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2015-01-21 16:15:592015-04-10 19:12:33Prolong Pharmaceuticals Moves Into New Headquarters
Abraham Abuchowski, Ph.D., considered the father of PEGylation...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/01/abevideopost.jpg?time=1601810496138250IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2015-01-13 22:06:202015-04-09 23:36:34Father of PEGylation to Receive Dr. Sol J. Barer Award at Gateway Gala, BioNJ’s 22st Annual Dinner Meeting, Networking Event and Innovation Celebration
Patients with sickle cell anemia (SCD) are at increased stroke risk. Periodic blood transfusions decrease tim-averaged mean of the maximum velocities of...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/henryfordmg.png?time=1601810496112130IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2014-09-11 17:15:372015-04-09 17:19:42Use of SANGUINATE in encephalopathy from severe sickle cell disease
Over the past two decades, the decision process for siting overseas clinical trials has become more complex for U.S. pharmaceutical companies. Once a straightforward analysis rooted in time and money, longer-term strategic issues...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/appliedclinical_logo.png?time=160181049628130IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2014-09-01 17:08:222015-04-09 17:10:47Strategic Approach Needed for International Clinical Trials
The first act in the story of sickle cell disease, one of the oldest known genetic diseases, is not a happy one. Aside from a very small number of young patients undergoing successful bone marrow or stem cell transplants, there is no curative treatment...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2014/04/pharexec.png?time=160181049631130IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2014-04-22 21:59:212015-04-10 19:18:08Sickle Cell Disease In Three Acts
SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/prolongnews2.jpg?time=160181049636125IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2013-12-18 17:20:552016-09-06 14:35:06Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team
Attacking one disease is challenging enough, but what if you can attack a disease that produces multiple disorders? Answering that question motivates Prolong Pharmaceuticals LLC, a South Plainfield biotech company developing...
https://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/njbiz.png?time=16018104963988IT Serviceshttps://secureservercdn.net/50.62.88.87/779.8e1.myftpupload.com/wp-content/uploads/2015/04/ProlongLOGO-RedText-12k-250w.pngIT Services2013-12-13 21:54:142015-04-10 19:14:10Prolong’s approach: Taking on multiple diseasesCompany confident Sanguinate can be difference-maker
Prolong Pharmaceuticals Presents Data on Unique “Un-Sickling” In Vitro Activity Observed in Sickle Cell Investigational Drug SANGUINATE™
Prolong Pharmaceuticals’ Flagship Product SANGUINATE™ Granted Orphan Drug Designation by the FDA
Prolong Expands Operations (& Potential for Success)
Prolong Pharmaceuticals Moves Into New Headquarters
Father of PEGylation to Receive Dr. Sol J. Barer Award at Gateway Gala, BioNJ’s 22st Annual Dinner Meeting, Networking Event and Innovation Celebration
Use of SANGUINATE in encephalopathy from severe sickle cell disease
Strategic Approach Needed for International Clinical Trials
Sickle Cell Disease In Three Acts
Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team
Prolong’s approach: Taking on multiple diseasesCompany confident Sanguinate can be difference-maker